Skip To Main Content
Martin Dunbar on Muck Rack

Martin Dunbar

As seen in: Taylor & Francis Online, Dove Medical Press, The Journal of Clinical Psychiatry
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Martin

Contact Martin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Full article: Aripiprazole Lauroxil Every 2 Months or Paliperidone Palmitate Monthly for Acute Schizophrenia: A Post Hoc Analysis of PANSS Five-Factor Scores in the ALPINE Trial

|
By Leslie Citrome, Martin Dunbar, James McGrory
| Taylor & Francis Online
Abstract Purpose The randomized, controlled Aripiprazole Lauroxil and Paliperidone palmitate: INitiation Effectiveness (ALPINE) study (NCT03345979) evaluated the efficacy and safety of aripiprazole lauroxil (AL) administered every-2-months in patients with schizophrenia. Primary results indicating significant improvement in Positive and Negative Syndrome Scale (PANSS) total scores with AL or active control (paliperidone palmitate [PP] monthly) were reported previously.
Open in Who Shared Issue with article?

Aripiprazole lauroxil every 2 months for acute schizophrenia: a post h

|
By Leslie Citrome, Martin Dunbar, James McGrory
| Dove Medical Press
Back to Journals » Neuropsychiatric Disease and Treatment » Volume 21 Authors Citrome L , Dunbar M, McGrory JA Received 5 December 2024 Accepted for publication 25 April 2025 Published 14 May 2025 Volume 2025:21 Pages 1047—1055 DOI https://doi.org/10.2147/NDT.S510471 Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 3 Editor who approved publication: Dr Taro Kishi Leslie Citrome,1 Martin Dunbar,2 James A McGrory2 1Department of Psychiatry and Behavioral...
Open in Who Shared Issue with article?

Long-Term Safety and Treatment Effect of Olanzapine/Samidorphan

|
By Jacob Ballon, René S. Kahn, Christina Arevalo, Martin Dunbar
| The Journal of Clinical Psychiatry Verified
Abstract Objective: Evaluate long-term safety, tolerability, and durability of the effect of olanzapine/samidorphan (OLZ/SAM) for up to 4 years in patients with schizophrenia, schizophreniform disorder, or bipolar I disorder (BD-I). Methods: This phase 3, multicenter, open-label, long-term extension (conducted June 2017–September 2023) assessed OLZ/SAM in patients completing the ENLIGHTEN clinical program. Patients received ≥2–4 years of additional treatment.
Open in Who Shared Issue with article?
See all 4 articles